Current/JJ
Status/NN
and/CC
Future/JJ
Clinical/JJ
Applications/NNS
of/IN
Array/NN
based/VBN
Comparative/JJ
Genomic/JJ
Hybridization/NN
./.
====================
Constitutional/JJ
chromosomal/JJ
alterations/NNS
are/VBP
commonly/RB
====================
detected/VBN
features/NNS
in/IN
various/JJ
human/JJ
diseases/NNS
such/JJ
as/IN
tumor/NN
,/,
congenital/JJ
anomalies/NNS
,/,
psychiatric/JJ
disorders/NNS
,/,
and/CC
metabolic/JJ
disorders/NNS
./.
====================
Neoplastic/JJ
transformations/NNS
,/,
for/IN
example/NN
,/,
are/VBP
initiated/VBN
by/IN
the/DT
aberrations/NNS
of/IN
genes/NNS
regulating/VBG
cell/NN
proliferation/NN
,/,
apoptosis/NN
,/,
genome/NN
stability/NN
,/,
angiogenesis/NN
,/,
invasion/NN
and/CC
metastasis/NN
(/(
Hanahan/NN
and/CC
Weinberg/NN
,/,
2000/CD
)/)
./.
====================
Through/IN
the/DT
population/NN
genetics/NNS
studies/NNS
,/,
some/DT
tumor/NN
suppresor/NN
genes/NNS
and/CC
oncogenes/NNS
have/VBP
been/VBN
verified/VBN
(/(
Wakabayashi/NNP
etal./FW
,/,
2003/CD
;/:
Huges/NNS
et/FW
al./FW
,/,
2001/CD
;/:
Wilentz/NNP
et/FW
al./FW
,/,
2001/CD
;/:
Herranz/RB
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
And/CC
the/DT
causative/JJ
chromosomal/JJ
alterations/NNS
for/IN
some/DT
congenital/JJ
genetic/JJ
disorders/NNS
have/VBP
been/VBN
identified/VBN
by/IN
conventional/JJ
cytogenetic/JJ
tools/NNS
./.
====================
However/RB
,/,
there/EX
will/MD
be/VB
even/RB
more/RBR
unknown/JJ
tumor-related/JJ
genes/NNS
,/,
supposedly/RB
up/IN
to/TO
several/JJ
hundreds/VBZ
,/,
yet/RB
to/TO
be/VB
found/VBN
(/(
Balmain/NNP
,/,
2002/CD
)/)
,/,
and/CC
still/RB
a/DT
lot/JJ
of/IN
idiopathic/JJ
psychiatric//JJ
metabolic/JJ
disorders/NNS
of/IN
unknown/JJ
origin/NN
./.
====================
In/IN
this/DT
aspect/NN
,/,
precise/JJ
detection/NN
of/IN
the/DT
breakpoint/NN
of/IN
chromosomal/JJ
dosage/NN
change/NN
,/,
together/RB
with/IN
the/DT
functional/JJ
and/CC
clinical/JJ
studies/NNS
,/,
is/VBZ
essential/JJ
to/TO
understand/VB
the/DT
causes/VBZ
of/IN
these/DT
disorders/NNS
and/CC
to/TO
prevent/VB
them/PRP
./.
====================
Microarray/NN
technology/NN
makes/VBZ
it/PRP
possible/JJ
to/TO
do/VBP
high-/JJ
throughput/NN
and/CC
high-resolution/JJ
analysis/NN
./.
====================
Combination/NN
of/IN
conventional/JJ
comparative/JJ
genomic/JJ
hybridization/NN
(/(
CGH/NN
)/)
and/CC
microarray/NN
technology/NN
promises/VBZ
us/PRP
genome-wide/NN
high-resolution/JJ
DNA/NN
copy/NN
number/NN
analysis/NN
./.
====================
We/PRP
review/VBP
here/RB
the/DT
recent/JJ
progress/NN
of/IN
the/DT
array/NN
based/VBN
CGH/NN
====================
(/(
A-CGH/NN
)/)
technology/NN
and/CC
its/PRP$
clinical/JJ
applications/NNS
./.
====================
investigate/VB
the/DT
type/NN
and/CC
location/NN
of/IN
DNA/NN
copy/NN
number/NN
changes/NNS
across/IN
whole/JJ
genome/NN
(/(
Kallioniemi/NN
et/FW
al./FW
,/,
1992/CD
)/)
./.
====================
This/DT
technique/NN
is/VBZ
based/VBN
on/IN
the/DT
principle/JJ
that/DT
test/VBP
DNA/NN
and/CC
reference/VBP
DNA/NN
,/,
labeled/VBN
with/IN
different/JJ
fluorescent/JJ
dyes/NNS
,/,
are/VBP
competitively/RB
hybridized/VBD
to/TO
normal/JJ
metaphase/NN
chromosomes/NNS
./.
====================
The/DT
ratio/NN
of/IN
the/DT
two/CD
fluorescence/NN
intensities/NNS
detected/VBN
is/VBZ
indicative/JJ
of/IN
the/DT
relative/JJ
DNA/NN
copy/NN
number/NN
differences/NNS
in/IN
test/NN
versus/CC
reference/NN
DNA/NN
./.
====================
If/IN
both/CC
genomic/JJ
DNA/NN
have/VBP
the/DT
same/JJ
allelic/JJ
copy/NN
number/NN
,/,
the/DT
ratio/NN
will/MD
be/VB
1/CD
./.
====================
If/IN
there/EX
is/VBZ
a/DT
single/JJ
copy/NN
deletion/NN
in/IN
one/CD
allele/NN
,/,
then/RB
the/DT
ratio/NN
will/MD
be/VB
0.5/CD
and/CC
in/IN
the/DT
case/NN
of/IN
copy/NN
number/NN
gains/NNS
,/,
the/DT
ratio/NN
will/MD
be/VB
3:2/CD
(/(
single/JJ
copy/NN
gain/NN
)/)
or/CC
4:2/CD
(/(
2/CD
copy/NN
gain/NN
)/)
or/CC
more/RBR
./.
====================
When/WRB
the/DT
chromosome-wide/NN
fluorescence/NN
ratio/NN
data/NNS
is/VBZ
combined/VBN
with/IN
chromosome/NN
banding/NN
data/NNS
,/,
we/PRP
can/MD
locate/VB
the/DT
global/JJ
copy/NN
number/NN
changes/NNS
./.
====================
This/DT
concept/NN
of/IN
CGH/NN
introduced/VBN
a/DT
new/JJ
paradigm/NN
of/IN
chromosome/NN
analysis/NN
./.
====================
Conventional/JJ
karyotyping/VBG
needs/VBZ
metaphase/NN
chromosome/NN
spread/VBN
from/IN
the/DT
test/NN
tissue/NN
./.
====================
Tissue/NN
culture/NN
is/VBZ
time/NN
consuming/VBG
and/CC
most/JJS
of/IN
the/DT
disease/NN
tissues/NNS
are/VBP
not/RB
available/JJ
for/IN
metaphase/NN
preparation/NN
in/IN
practice/NN
./.
====================
Even/RB
though/IN
we/PRP
could/MD
get/VB
the/DT
metaphase/NN
spread/VBN
,/,
it/PRP
is/VBZ
very/RB
difficult/JJ
to/TO
interpret/VB
and/CC
locate/VB
the/DT
regional/JJ
gain/NN
or/CC
loss/NN
by/IN
karyotyping/VBG
./.
====================
CGH/NN
technology/NN
renders/VBZ
us/PRP
to/TO
overcome/VB
the/DT
difficulties/NNS
of/IN
karyotyping/VBG
and/CC
improve/VBP
quality/NN
of/IN
analysis/NN
./.
====================
For/IN
example/NN
,/,
commercialized/VBD
normal/JJ
chromosome/NN
slide/NN
could/MD
be/VB
used/VBN
instead/RB
of/IN
a/DT
metaphase/NN
chromosome/NN
from/IN
the/DT
test/NN
tissue/NN
./.
====================
With/IN
this/DT
new/JJ
concept/NN
,/,
we/PRP
could/MD
also/RB
circumvent/JJ
several/JJ
limitations/NNS
of/IN
loss/NN
of/IN
heterozygosity/NN
(/(
LOH/NN
)/)
analysis/NN
,/,
another/DT
common/JJ
approach/NN
to/TO
analyze/VB
the/DT
allelic/JJ
dosage/NN
changes/NNS
./.
====================
Firstly/RB
,/,
CGH/NN
enables/VBZ
genome­/NN
wide/JJ
investigation/NN
by/IN
single/JJ
hybridization/NN
./.
====================
By/IN
LOH/NN
analysis/NN
,/,
theoretically/RB
,/,
several/JJ
thousands/NNS
of/IN
microsatellite/NN
marker/NN
PCR/NN
and/CC
electrophoreses/NNS
should/MD
be/VB
performed/VBN
for/IN
the/DT
genome-wide/NN
analysis/NN
with/IN
similar/JJ
resolution/NN
./.
====================
To/TO
achieve/VB
high-resolution/JJ
genome-wide/NN
screening/NN
,/,
LOH/NN
analysis/NN
is/VBZ
expensive/JJ
and/CC
time-/NN
consuming/VBG
./.
====================
Secondly/RB
,/,
CGH/NN
can/MD
distinguish/VB
between/IN
loss/NN
and/CC
gain/NN
of/IN
genetic/JJ
material/NN
contrary/NN
to/TO
LOH/NN
analysis/NN
./.
====================
Using/VBG
CGH/JJ
technology/NN
,/,
a/DT
lot/JJ
of/IN
cancer/NN
related/JJ
chromosomal/JJ
alterations/NNS
have/VBP
been/VBN
identified/VBN
from/IN
various/JJ
tumors/NNS
(/(
Mathew/JJ
etal./FW
,/,
2003/CD
;/:
Balsara/NNP
and/CC
Testa/NN
,/,
2002/CD
;/:
Buerger/NNP
et/FW
al./FW
,/,
1999/CD
;/:
Nessling/VBG
etal./FW
,/,
1998/CD
;/:
Wolf/NNP
etal./FW
,/,
1999/CD
;/:
Ried/VBN
etal./FW
,/,
1995/CD
)/)
./.
====================
However/RB
CGH/NN
also/RB
has/VBZ
its/PRP$
own/JJ
limitations/NNS
./.
====================
The/DT
resolution/NN
of/IN
CGH/NN
is/VBZ
not/RB
high/JJ
enough/IN
(/(
10-20/CD
Mb/NN
)/)
to/TO
localize/VB
regional/JJ
chromosome/NN
imbalances/NNS
,/,
which/WDT
are/VBP
commonly/RB
detected/VBN
in/IN
tumors/NNS
(/(
Knuutila/NN
etal./FW
,/,
1999/CD
;/:
Ried/VBN
====================
etal./FW
,/,
1999/CD
)/)
./.
====================
For/IN
scoring/VBG
the/DT
low/JJ
resolution/NN
chromosome/NN
banding/NN
,/,
researchers/NNS
need/VBD
to/TO
be/VB
highly/RB
experienced/VBN
./.
====================
Because/IN
of/IN
these/DT
limitations/NNS
,/,
results/VBZ
from/IN
some/DT
less/RBR
experienced/VBN
laboratories/NNS
were/VBD
not/RB
trustworthy/JJ
nor/CC
valid/NN
./.
====================
But/CC
still/RB
CGH/NN
is/VBZ
an/DT
attractive/JJ
method/NN
to/TO
investigate/VB
genetic/JJ
imbalances/NNS
for/IN
tumorigenesis/NN
up/IN
to/TO
now/RB
./.
====================
Scientists/NNS
have/VBP
been/VBN
attempting/VBG
to/TO
surmount/VB
low/JJ
resolution/NN
of/IN
CGH/NN
and/CC
accentuate/VBP
its/PRP$
advantages/NNS
by/IN
combining/VBG
CGH/NN
and/CC
microarray/NN
(/(
Pollack/NN
et/FW
al./FW
,/,
1999/CD
;/:
Albertson/NN
and/CC
Pinkel/NN
,/,
2003/CD
)/)
./.
====================
100-200/CD
kb/NN
sized/VBN
bacterial/JJ
artificial/JJ
chromosomes/NNS
(/(
BAC/NN
)/)
clones/NNS
are/VBP
used/VBN
to/TO
build/JJ
tile-path/NN
covering/VBG
all/DT
the/DT
autosomal/JJ
and/CC
sex/NN
chromosomes/NNS
,/,
from/IN
which/WDT
array/VBP
chips/NNS
are/VBP
produced/VBN
for/IN
CGH/NN
analysis/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
use/NN
of/IN
insert/NN
genomic/JJ
clones/NNS
such/JJ
as/IN
BACs/NNS
or/CC
PACs/NNS
for/IN
A-CGH/JJ
provides/VBZ
sufficiently/RB
intense/JJ
signals/NNS
so/RB
that/IN
accurate/VBP
measurements/NNS
can/MD
be/VB
obtained/VBN
for/IN
copy/NN
number/NN
change/NN
and/CC
direct/JJ
chromosomal/JJ
mapping/NN
is/VBZ
possible/JJ
./.
====================
Recent/JJ
development/NN
of/IN
the/DT
bioinformatics/NNS
tools/NNS
for/IN
A-CGH/JJ
analysis/NN
allows/VBZ
more/RBR
objective/NN
and/CC
accurate/VBP
localization/NN
of/IN
chromosome/NN
alterations/NNS
(/(
Jong/JJ
et/FW
al./FW
,/,
====================
2004/CD
;/:
Myers/NNS
et/FW
al./FW
,/,
2004/CD
;/:
Wang/NNP
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Furthermore/RB
,/,
since/IN
the/DT
array/NN
format/IN
lends/NNS
itself/PRP
to/TO
automation/NN
,/,
it/PRP
is/VBZ
possible/JJ
to/TO
minimize/VB
person-to-person/NN
variation/NN
./.
====================
With/IN
completion/NN
of/IN
Human/JJ
Genome/NNP
Project/JJ
draft/RB
in/IN
2001/CD
and/CC
Mouse/NN
Genome/NNP
Project/JJ
draft/RB
in/IN
2002/CD
making/VBG
map/VBP
of/IN
BAC/NN
clones/NNS
covering/VBG
whole/JJ
genome/NN
more/RBR
accurate/JJ
and/CC
refined/VBD
,/,
cancer/NN
researches/VBZ
using/VBG
A-CGH/JJ
are/VBP
being/VBG
more/RBR
facilitated/JJ
(/(
Pinkel/NN
et/FW
al./FW
,/,
1998/CD
;/:
Hodgson/NNP
et/FW
al./FW
,/,
2001/CD
;/:
Snijders/NNS
et/FW
al./FW
,/,
2001/CD
;/:
Cai/NNP
et/FW
al./FW
,/,
2002/CD
;/:
O/NNP
’/NNP
Hagan/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Albertson/NNP
,/,
2003/CD
)/)
./.
====================
Even/RB
though/IN
A-CGH/NN
greatly/RB
improved/JJ
in/IN
array/NN
production/NN
and/CC
analysis/NN
,/,
it/PRP
can/MD
not/RB
be/VB
omnipotent/JJ
./.
====================
It/PRP
is/VBZ
important/JJ
to/TO
remember/VB
that/DT
A-CGH/JJ
does/VBZ
not/RB
provide/VB
information/NN
on/IN
reciprocal/JJ
translocation/NN
or/CC
polyploidy/NN
./.
====================
First/RB
step/NN
to/TO
construction/NN
of/IN
genomic/JJ
arrays/NNS
is/VBZ
to/TO
prepare/VB
the/DT
set/NN
of/IN
BAC/NN
clones/NNS
covering/VBG
whole/JJ
human/JJ
genome/NN
./.
====================
There/EX
are/VBP
several/JJ
different/JJ
types/NNS
of/IN
artificial/JJ
chromosomes/NNS
====================
carrying/VBG
human/JJ
genome/NN
;/:
Bacterial/JJ
artificial/JJ
chromosome/NN
(/(
BAC/NN
)/)
,/,
Yeast/NN
artificial/JJ
chromosome/NN
(/(
YAC/NN
)/)
,/,
P1/NN
bacteriophage/JJ
artificial/JJ
chromosome/NN
(/(
PAC/NN
)/)
and/CC
cosmid/NN
./.
====================
BAC/NN
clone/NN
is/VBZ
the/DT
most/JJS
popular/JJ
resource/NN
for/IN
A-CGH/JJ
fabrication/NN
./.
====================
The/DT
size/NN
of/IN
insert/NN
is/VBZ
different/JJ
from/IN
host/NN
to/TO
host/NN
./.
====================
For/IN
example/NN
,/,
BAC/NN
can/MD
carry/VB
about/RB
200/CD
kb/NN
,/,
YAC/NN
0.2-2/CD
Mb/NN
,/,
and/CC
PAC/NN
130-150/CD
kb/NN
at/IN
maximum/NN
respectively/RB
./.
====================
Even/RB
though/IN
spotting/VBG
DNA/NN
directly/RB
onto/IN
the/DT
slide/JJ
is/VBZ
the/DT
simplest/JJS
and/CC
most/JJS
accurate/JJ
way/NN
,/,
it/PRP
is/VBZ
not/RB
always/RB
easy/RB
in/IN
practice/NN
./.
====================
Firstly/RB
,/,
since/IN
BAC/NN
is/VBZ
single/JJ
copy/NN
,/,
yields/VBZ
of/IN
BAC/NN
DNA/NN
are/VBP
low/JJ
./.
====================
Secondly/RB
,/,
high-molecular/JJ
DNA/NN
sized/VBN
more/RBR
than/IN
100/CD
kb/NN
from/IN
BACs/NNS
can/MD
be/VB
viscous/JJ
,/,
blocking/VBG
the/DT
spotting/JJ
needles/NNS
intermittently/RB
./.
====================
Therefore/RB
,/,
researchers/NNS
have/VBP
to/TO
do/VBP
large/JJ
amount/NN
bacterial/JJ
cultures/NNS
and/CC
sonicate/NN
the/DT
DNA/NN
to/TO
reduce/VB
the/DT
molecular/JJ
weight/NN
down/RB
(/(
Pinkel/NN
etal./FW
,/,
1998/CD
;/:
Cai/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
To/TO
overcome/VB
these/DT
limitations/NNS
again/RB
,/,
new/JJ
technique/NN
was/VBD
adopted/VBN
;/:
extract/NN
small/JJ
amount/NN
of/IN
BAC/NN
DNA/NN
automatically/RB
from/IN
large/JJ
number/NN
of/IN
small/JJ
scaled/VBN
culture/NN
and/CC
amplify/VBP
them/PRP
by/IN
using/VBG
whole/JJ
genome/NN
amplification/NN
such/JJ
as/IN
,/,
ligation/NN
mediated/VBN
PCR/NN
(/(
Snijders/NNS
et/FW
al./FW
,/,
2001/CD
;/:
Klein/NNP
etal./FW
,/,
1999/CD
)/)
ordegenerated/VBN
oligonucleotide/JJ
primed/VBN
(/(
DOP/NN
)/)
(/(
Hodgson/NN
et/FW
al./FW
,/,
2001/CD
;/:
Veltman/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Another/DT
new/JJ
approach/NN
enabling/VBG
construction/NN
of/IN
arrays/NNS
from/IN
minute/JJ
amount/NN
of/IN
DNA/NN
is/VBZ
rolling/NN
circle/NN
amplification/NN
(/(
Dean/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
This/DT
rolling/NN
circle/NN
amplified/VBN
products/NNS
were/VBD
proved/VBN
to/TO
be/VB
a/DT
suitable/JJ
resource/NN
for/IN
A-CGH/JJ
(/(
Smirnov/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
This/DT
approach/NN
could/MD
also/RB
be/VB
used/VBN
for/IN
small/JJ
amount/NN
of/IN
tissue/NN
(/(
Lage/NN
et/FW
al./FW
,/,
2003/CD
;/:
Paris/NN
etal./FW
,/,
2003/CD
)/)
./.
====================
These/DT
novel/JJ
techniques/NNS
are/VBP
to/TO
amplify/VB
target/NN
sequences/NNS
in/IN
BAC/NN
clones/NNS
nonspecifically/RB
across/IN
the/DT
whole/JJ
genome/NN
,/,
therefore/RB
it/PRP
could/MD
represent/VB
genomic/JJ
complexity/NN
./.
====================
DOP/NN
amplification/NN
is/VBZ
the/DT
most/JJS
commonly/RB
used/VBN
method/NN
for/IN
array/NN
preparation/NN
nowadays/RB
./.
====================
Figure/NN
2/CD
represents/VBZ
the/DT
example/NN
of/IN
DOP/NN
primer/NN
and/CC
amplification/NN
of/IN
BAC/NN
DNA/NN
by/IN
DOP/NN
PCR/NN
./.
====================
Recently/RB
,/,
species/NNS
specifically/RB
designed/VBN
DOP/NN
PCR/NN
was/VBD
developed/VBN
enabling/VBG
more/RBR
specific/JJ
amplification/NN
of/IN
target/NN
sequences/NNS
and/CC
minimizing/JJ
match/VBP
with/IN
bacterial/JJ
DNA/NN
at/IN
the/DT
same/JJ
time/NN
,/,
which/WDT
can/MD
make/VB
array/NN
CGH/NN
result/NN
more/RBR
valid/JJ
(/(
Fiegler/NN
etal./FW
,/,
2003/CD
;/:
Chung/JJ
etal./FW
,/,
2004/CD
)/)
./.
====================
There/EX
is/VBZ
a/DT
new/JJ
technique/NN
minimizing/VBG
repetitive/JJ
sequences/NNS
with/IN
primers/NNS
targeting/VBG
for/IN
non-repetitive/JJ
sequences/NNS
only/RB
(/(
Buckley/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Using/VBG
this/DT
approach/NN
,/,
repeat-free/JJ
sequences/NNS
are/VBP
amplified/VBN
by/IN
PCR/NN
from/IN
genomic/JJ
clones/NNS
and/CC
are/VBP
spotted/VBN
in/IN
pools/NNS
as/IN
targets/NNS
on/IN
a/DT
slide/JJ
./.
====================
DNA/NN
copy/NN
number/NN
changes/NNS
can/MD
also/RB
be/VB
detected/VBN
using/VBG
arrays/NNS
made/VBD
from/IN
cDNAs/NNS
or/CC
oligonucleotides/NNS
(/(
Lucito/NN
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
The/DT
cDNA/NN
arrays/NNS
have/VBP
proven/VBN
their/PRP$
ability/NN
to/TO
detect/VB
large/JJ
copy/NN
number/NN
changes/NNS
like/IN
amplification/NN
,/,
but/CC
the/DT
actual/JJ
genomic/JJ
resolution/NN
of/IN
the/DT
boundaries/NNS
of/IN
single/JJ
copy/NN
number/NN
change/NN
,/,
especially/RB
focal/JJ
single/JJ
copy/NN
change/NN
is/VBZ
considerably/RB
less/RBR
than/IN
that/DT
of/IN
BAC/NN
arrays/NNS
./.
====================
The/DT
resolution/NN
of/IN
BAC/NN
array/NN
has/VBZ
considerably/RB
improved/VBD
since/IN
the/DT
first/JJ
application/NN
of/IN
genome-wide/NN
array/NN
CGH/NN
for/IN
tumor/NN
analysis/NN
./.
====================
Dumanski/IN
group/NN
constructed/VBD
tile/JJ
path/NN
array/NN
for/IN
chromosome/NN
22/CD
and/CC
analyzed/VBD
some/DT
congenital/JJ
and/CC
neoplastic/JJ
diseases/NNS
(/(
Buckley/NNP
et/FW
a/DT
!/JJ
./.
,/,
2002/CD
)/)
./.
====================
In/IN
2003/CD
,/,
human/JJ
BAC/NN
array/NN
with/IN
proper/JJ
1/CD
Mb/NN
resolution/NN
has/VBZ
developed/VBN
(/(
Fiegler/NN
et/FW
al./FW
,/,
2003/CD
)/)
and/CC
recently/RB
full/JJ
coverage/NN
tile/JJ
path/NN
human/JJ
BAC/NN
array/NN
was/VBD
completed/VBN
(/(
Ishkanian/JJ
etal./FW
,/,
2004/CD
)/)
./.
====================
In/IN
mouse/NN
study/NN
,/,
Hodgson/NN
et/FW
al/JJ
./.
====================
applied/VBN
mouse/NN
BAC/NN
array/NN
for/IN
pancreatic/JJ
islet/NN
cell/NN
tumor/NN
analysis/NN
(/(
2001/CD
)/)
./.
====================
Cai/NN
et/FW
al/JJ
./.
====================
made/VBD
BAC/NN
array/NN
with/IN
3/CD
Mb/NN
interval/JJ
(/(
2002/CD
)/)
and/CC
Chung/JJ
et/FW
al/JJ
./.
====================
improved/VBN
the/DT
resolution/NN
to/TO
1/CD
Mb/NN
level/NN
(/(
2004/CD
)/)
./.
====================
Recent/JJ
development/NN
of/IN
bioinformatics/NNS
tools/NNS
for/IN
accurate/JJ
identification/NN
of/IN
aneuploidy/NN
breakpoint/NN
and/CC
smoothing/JJ
of/IN
A-CGH/JJ
data/NNS
is/VBZ
another/DT
optimistic/JJ
sign/NN
of/IN
further/JJ
standardization/NN
and/CC
application/NN
of/IN
A-CGH/JJ
for/IN
medical/JJ
researches/NNS
(/(
Jong/JJ
etal./FW
,/,
2004/CD
;/:
Myers/NNS
etal./FW
,/,
2004/CD
;/:
Wang/NNP
etal./FW
,/,
2004/CD
)/)
./.
====================
Figure/NN
3/CD
demonstrates/VBZ
the/DT
example/NN
of/IN
identification/NN
of/IN
breakpoint/NN
using/VBG
aCGH-Smooth/DT
software/JJ
(/(
Jong/JJ
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Because/IN
of/IN
these/DT
outstanding/VBG
progress/VBP
of/IN
A-CGH/JJ
technology/NN
,/,
more/RBR
than/IN
150/CD
research/NN
papers/NNS
using/VBG
A-CGH/JJ
have/VBP
been/VBN
published/VBN
during/IN
past/NN
6/CD
months/NNS
./.
====================
The/DT
easiest/JJS
application/NN
of/IN
A-CGH/JJ
is/VBZ
detection/NN
of/IN
multi-copy/JJ
gain/NN
of/IN
DNA/NN
extracted/VBN
from/IN
homogeneous/JJ
cell/NN
lines/NNS
./.
====================
In/IN
this/DT
case/NN
,/,
both/CC
test/NN
and/CC
reference/VBP
cells/NNS
are/VBP
pure/JJ
and/CC
the/DT
test/NN
DNA/NN
has/VBZ
much/RB
more/RBR
genetic/JJ
materials/NNS
than/IN
reference/NN
./.
====================
In/IN
many/JJ
studies/NNS
adopting/VBG
A-CGH/JJ
,/,
genomic/JJ
amplification/NN
is/VBZ
more/RBR
commonly/RB
detected/VBN
than/IN
single/JJ
copy/NN
deletion/NN
(/(
Hodgson/NN
et/FW
al./FW
,/,
2001/CD
;/:
Snijders/NNS
et/FW
al./FW
,/,
2001/CD
;/:
Cai/NNP
etal./FW
,/,
2002/CD
;/:
O/NNP
’/CD
Hagan/NN
etal./FW
,/,
2002/CD
)/)
./.
====================
Figure/NN
4/CD
====================
represents/VBZ
the/DT
precise/JJ
detection/NN
of/IN
Ras/NN
amplification/NN
by/IN
A-CGH/NN
in/IN
murine/JJ
mammary/JJ
tumor/NN
./.
====================
Detection/NN
of/IN
single/JJ
copy/NN
number/NN
change/NN
is/VBZ
relatively/RB
hard/JJ
,/,
especially/RB
in/IN
====================
narrow/JJ
regions/NNS
./.
====================
In/IN
single/JJ
copy/NN
deletion/NN
,/,
in/IN
principle/JJ
,/,
signal/NN
intensity/NN
of/IN
test/NN
DNA/NN
is/VBZ
reduced/VBN
50/CD
%/NN
than/IN
reference/NN
DNA/NN
;/:
and/CC
single/JJ
copy/NN
gain/NN
makes/VBZ
1.5/CD
times/NNS
more/RBR
intense/JJ
signal/NN
./.
====================
The/DT
result/NN
could/MD
be/VB
obscured/VBN
due/JJ
to/TO
multiple/JJ
factors/NNS
discussed/VBN
below/IN
./.
====================
Since/IN
the/DT
major/JJ
proportion/NN
of/IN
human/JJ
genome/NN
is/VBZ
repetitive/JJ
sequences/NNS
,/,
it/PRP
is/VBZ
important/JJ
to/TO
block/VB
repetitive/JJ
sequences/NNS
for/IN
reducing/VBG
background/NN
noise/RB
and/CC
obtaining/VBG
valid/JJ
hybridization/NN
result/NN
in/IN
genomic/JJ
DNA/NN
arrays/NNS
comparing/VBG
to/TO
expression/NN
array/NN
./.
====================
As/IN
well/RB
as/IN
blocking/VBG
repetitive/JJ
sequences/NNS
,/,
multiple/JJ
factors/NNS
like/IN
normal/JJ
cell/NN
contamination/NN
,/,
non-specific/JJ
interaction/NN
of/IN
labeled/JJ
DNA/NN
to/TO
glass/NN
surface/NN
,/,
uneven/JJ
hybridization/NN
,/,
washing/VBG
condition/NN
,/,
scanning/VBG
variation/NN
,/,
data/NNS
normalization/NN
can/MD
affect/VB
the/DT
result/NN
significantly/RB
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
establish/VB
adequate/NN
controls/NNS
and/CC
arrange/NN
every/RB
step/NN
carefully/RB
beforehand/CC
to/TO
detect/VB
valid/NN
single/JJ
====================
copy/NN
number/NN
change/NN
./.
====================
The/DT
enhanced/VBN
resolution/NN
and/CC
reproducibility/NN
of/IN
A-CGH/JJ
compared/VBN
with/IN
chromosome/NN
CGH/NN
has/VBZ
been/VBN
demonstrated/VBN
by/IN
the/DT
fact/NN
that/IN
A-CGH/JJ
could/MD
find/VB
the/DT
subtle/JJ
copy/NN
number/NN
aberrations/NNS
that/IN
were/VBD
not/RB
detected/VBN
by/IN
chromosome/NN
CGH/NN
./.
====================
For/IN
example/NN
,/,
in/IN
breast/NN
cancer/NN
,/,
amplification/NN
found/VBN
in/IN
20q13.2/CD
and/CC
CYP24/NN
gene/NN
was/VBD
proved/VBN
as/IN
oncogene/NN
for/IN
breast/NN
cancer/NN
after/IN
analysis/NN
(/(
Albertson/NN
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
In/IN
neurofibromatosis/NN
type2/NN
patient/NN
,/,
frequency/NN
and/CC
boundary/NN
of/IN
genetic/JJ
deletion/NN
in/IN
22q/JJ
was/VBD
found/VBN
accurately/RB
by/IN
A-CGH/JJ
(/(
Buckley/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Recently/RB
,/,
genetic/JJ
alterations/NNS
in/IN
wide-spectrum/NN
of/IN
tumors/NNS
have/VBP
been/VBN
analyzed/VBN
using/VBG
A-CGH/JJ
./.
====================
Numerous/JJ
novel/JJ
amplifications/NNS
have/VBP
been/VBN
found/VBN
in/IN
pancreatic/JJ
cancer/NN
,/,
osteosarcoma/NN
,/,
fallopian/JJ
tube/NN
carcinoma/NN
,/,
and/CC
head/RB
and/CC
neck/NN
cancers/NNS
(/(
Redon/NN
etal./FW
,/,
2002/CD
;/:
Snijders/NNS
et/FW
al./FW
,/,
2003/CD
;/:
Holzmann/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Man/JJ
etal./FW
,/,
2004/CD
)/)
./.
====================
Whole/IN
chromosome/NN
profiling/VBG
of/IN
lymphomas/NNS
and/CC
gastrointestinal/JJ
tumors/NNS
were/VBD
also/RB
comprehensively/RB
analyzed/VBD
(/(
De/NNP
Leeuw/NNP
etal./FW
,/,
2004/CD
;/:
Peng/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
A-CGH/JJ
can/MD
be/VB
used/VBN
to/TO
analyze/VB
genome-/NN
widely/RB
for/IN
each/DT
stage/NN
of/IN
tumor/NN
genesis/NN
./.
====================
Animal/JJ
disease/NN
models/NNS
are/VBP
actively/RB
studied/VBN
using/VBG
A-CGH/JJ
./.
====================
Deletions/NNS
in/IN
chromosomes/NNS
6,8/CD
,/,
and/CC
4/CD
(/(
12p11/CD
-p13/NN
,/,
16q24.3/CD
,/,
13q11-32/NN
in/IN
human/JJ
)/)
and/CC
amplifications/NNS
in/IN
chromosomes/NNS
2/CD
and/CC
4/CD
(/(
20q13.2/CD
,/,
1p32-36/NN
in/IN
human/JJ
)/)
were/VBD
found/VBN
by/IN
A-CGH/JJ
in/IN
mouse/NN
pancreatic/JJ
islet/NN
cell/NN
tumor/NN
./.
====================
Among/IN
genes/NNS
in/IN
these/DT
regions/NNS
,/,
there/EX
are/VBP
several/JJ
candidates/NNS
for/IN
tumor/NN
suppressor/NN
genes/NNS
and/CC
oncogenes/NNS
like/IN
CYP24/NN
,/,
PFDN4/NN
,/,
STMN1/NN
,/,
CDK1B/NN
,/,
PPP2R3/NN
and/CC
FSTL1/NN
(/(
Hodgson/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
The/DT
genomic/JJ
instability/NN
affected/VBN
by/IN
telomere/NN
dysfunction/NN
was/VBD
studied/VBN
in/IN
colon/NN
and/CC
breast/NN
cancers/NNS
by/IN
using/VBG
A-CGH/JJ
(/(
O/NN
’/CD
Hagan/NN
et/FW
al./FW
,/,
====================
2002/CD
)/)
./.
====================
As/IN
a/DT
result/NN
,/,
minimal/JJ
amplification/NN
region/NN
(/(
MAR/NN
)/)
was/VBD
found/VBN
and/CC
regional/JJ
amplification/NN
or/CC
loss/NN
induced/VBD
by/IN
nonreciprocal/JJ
translocation/NN
due/JJ
to/TO
telomere/VB
dysfunction/NN
proved/VBD
to/TO
be/VB
one/CD
of/IN
the/DT
important/JJ
tumorigenesis/NN
mechanisms/NNS
./.
====================
A-CGH/JJ
analysis/NN
of/IN
murine/JJ
neurolastoma/NN
revealed/VBD
important/JJ
ideas/IN
to/TO
understand/VB
human/JJ
tumor/NN
progression/NN
(/(
Hackett/NN
etal./FW
,/,
2003/CD
)/)
./.
====================
It/PRP
is/VBZ
well-known/JJ
that/DT
a/DT
variety/NN
of/IN
quantitative/JJ
changes/NNS
in/IN
genetic/JJ
material/NN
underlie/VBP
many/JJ
congenital/JJ
anomalies/NNS
or/CC
mental/JJ
retardations/NNS
./.
====================
In/IN
practice/NN
,/,
several/JJ
cytogenetic/JJ
techniques/NNS
have/VBP
been/VBN
used/VBN
to/TO
diagnose/VB
these/DT
disorders/NNS
./.
====================
If/IN
the/DT
genetic/JJ
changes/NNS
are/VBP
already/RB
identified/VBN
,/,
we/PRP
can/MD
use/VB
karyotyping/VBG
or/CC
FISH/NN
to/TO
confirm/VB
genetic/JJ
abnormalities/NNS
such/JJ
as/IN
aneuploidy/NN
,/,
regional/JJ
loss/NN
or/CC
gain/NN
,/,
translocation/NN
./.
====================
But/CC
,/,
there/EX
is/VBZ
a/DT
limitation/NN
to/TO
use/VB
existing/VBG
molecular/JJ
genetic/JJ
techniques/NNS
for/IN
detecting/VBG
novel/JJ
or/CC
subtle/JJ
changes/NNS
because/IN
of/IN
technical/JJ
difficulties/VBZ
as/IN
we/PRP
mentioned/VBD
before/IN
./.
====================
Even/RB
though/IN
causative/JJ
genetic/JJ
abnormalities/NNS
for/IN
several/JJ
congenital/JJ
diseases/NNS
like/IN
Down/NN
syndrome/NN
are/VBP
already/RB
found/VBN
,/,
genetic/JJ
changes/NNS
causing/VBG
most/JJS
of/IN
congenital/JJ
anomalies/NNS
and/CC
mental/JJ
retardation/NN
are/VBP
still/RB
largely/RB
unknown/JJ
./.
====================
There/EX
are/VBP
evidences/NNS
that/DT
submicroscopic/JJ
telomeric/JJ
rearrangement/NN
is/VBZ
related/JJ
with/IN
mental/JJ
retardation/NN
./.
====================
Also/RB
the/DT
role/NN
of/IN
subtelomeric/JJ
rearrangement/NN
has/VBZ
been/VBN
revealed/VBN
directly/RB
and/CC
indirectly/RB
,/,
but/CC
not/RB
fully/RB
proven/VBN
./.
====================
Recent/JJ
researches/NNS
using/VBG
A-CGH/JJ
for/IN
congenital/JJ
diseases/NNS
have/VBP
been/VBN
finding/NN
clinically/RB
important/JJ
information/NN
./.
====================
For/IN
example/NN
,/,
new/JJ
A-CGH/NN
designed/VBN
to/TO
analyze/VB
telomeric/JJ
or/CC
====================
subtelomeric/JJ
region/NN
is/VBZ
now/RB
being/VBG
used/VBN
for/IN
studying/VBG
some/DT
idiopathic/JJ
mental/JJ
retardation/NN
(/(
Veltman/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Knight/NNP
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
A-CGH/JJ
not/RB
only/RB
confirmed/VBD
previous/JJ
hypotheses/NNS
for/IN
mental/JJ
retardations/NNS
of/IN
unknown/JJ
origin/NN
,/,
but/CC
also/RB
found/VBD
novel/JJ
changes/NNS
(/(
Veltman/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Indeed/RB
several/JJ
interesting/JJ
cryptic/JJ
rearrangement/NN
,/,
deletions/NNS
,/,
or/CC
duplications/NNS
were/VBD
detected/VBN
in/IN
subtelomeric/JJ
region/NN
of/IN
chromosome/NN
1/CD
,/,
4/CD
,/,
9/CD
,/,
15/CD
in/IN
idiopathic/JJ
mental/JJ
retardation/NN
(/(
Harada/NN
et/FW
al./FW
,/,
2004/CD
;/:
Shaw-Smith/IN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Other/JJ
types/NNS
of/IN
complex/NN
neurobehavioral/JJ
disorders/NNS
or/CC
unknown/JJ
spontaneous/JJ
miscarriage/NN
were/VBD
also/RB
studied/VBD
using/VBG
A-CGH/JJ
,/,
revealed/VBD
some/DT
causative/JJ
rearrangements/NNS
or/CC
imbalances/NNS
(/(
Schaeffer/NNP
etal./FW
,/,
2004/CD
;/:
Wang/NNP
etal/JJ
,/,
2004/CD
)/)
./.
====================
Even/RB
though/IN
this/DT
field/NN
is/VBZ
relatively/RB
new/JJ
and/CC
it/PRP
needs/VBZ
more/RBR
improvement/JJ
,/,
A-CGH/JJ
based/VBN
genetic/JJ
diagnosis/NN
will/MD
become/VB
clinically/RB
important/JJ
./.
====================
To/TO
see/VB
more/RBR
examples/NNS
,/,
A-CGH/JJ
revealed/VBD
the/DT
deletion/NN
boundary/NN
around/IN
22q11.2/CD
,/,
known/VBN
as/IN
an/DT
important/JJ
region/NN
for/IN
DiGeorge/JJ
syndrome/NN
(/(
Snijders/NNS
etal./FW
,/,
2001/CD
)/)
./.
====================
A-CGH/JJ
have/VBP
uncovered/JJ
important/JJ
changes/NNS
for/IN
cardio-facio-cutaneous/JJ
syndrome/NN
and/CC
other/JJ
congenital/JJ
disorders/NNS
like/IN
congenital/JJ
aural/JJ
atresia/NN
(/(
Rauen/NN
etal./FW
,/,
2002/CD
;/:
Veltman/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Gunn/NNP
etal./FW
,/,
2003/CD
)/)
./.
====================
CGH/NN
is/VBZ
expected/VBN
to/TO
contribute/VB
to/TO
biomedical/JJ
study/NN
enormously/RB
./.
====================
Cancers/NNS
are/VBP
caused/VBN
by/IN
multiple/JJ
genetic/JJ
changes/NNS
sporadically/RB
as/IN
well/RB
as/IN
congenitally/RB
./.
====================
It/PRP
has/VBZ
been/VBN
widely/RB
accepted/VBN
that/IN
on/IN
or/CC
off/IN
of/IN
a/DT
single/JJ
gene/NN
can/MD
not/RB
explain/VB
complicated/VBN
processes/NNS
of/IN
tumor/NN
initiation/NN
,/,
====================
development/NN
or/CC
metastasis/NN
./.
====================
To/TO
understand/VB
the/DT
complex/NN
network/NN
of/IN
genetic/JJ
alterations/NNS
from/IN
single/JJ
genes/NNS
to/TO
genome/NN
,/,
in/IN
addition/NN
to/TO
global/JJ
gene/NN
expression/NN
profiling/VBG
,/,
one/CD
of/IN
the/DT
key/JJ
information/NN
will/MD
be/VB
comprehensive/JJ
genome-wide/NN
chromosome/NN
aberration/NN
data/NNS
./.
====================
To/TO
overcome/VB
the/DT
limitations/NNS
of/IN
A-CGH/JJ
such/JJ
as/IN
tumor/NN
cell/NN
purity/NN
or/CC
isolation/NN
of/IN
single/JJ
tumor/NN
clone/NN
,/,
microdissection/NN
based/VBN
A-CGH/NN
analysis/NN
can/MD
be/VB
more/RBR
useful/JJ
./.
====================
This/DT
microdissection/NN
and/CC
whole/JJ
genome/NN
amplification/NN
based/VBN
approach/NN
is/VBZ
already/RB
applied/VBN
as/IN
an/DT
alternative/JJ
way/NN
to/TO
increase/VB
the/DT
tumor/NN
cell/NN
purity/NN
and/CC
to/TO
use/VB
extremely/RB
small/JJ
number/NN
of/IN
cells/NNS
for/IN
A-CGH/JJ
./.
====================
Using/VBG
A-CGH/JJ
we/PRP
can/MD
understand/VB
more/RBR
about/RB
idiopathic/JJ
genetic/JJ
diseases/NNS
,/,
psychiatric/JJ
diseases/NNS
,/,
and/CC
metabolic/JJ
disorders/NNS
./.
====================
There/EX
have/VBP
been/VBN
evidences/NNS
of/IN
chromosomal/JJ
alterations/NNS
in/IN
type/NN
1/CD
diabetes/VBZ
mellitus/NN
and/CC
autoimmune/JJ
disease/NN
like/IN
SLE/NN
./.
====================
Ultimately/RB
,/,
as/IN
shown/VBN
in/IN
figure/NN
5/CD
,/,
we/PRP
hope/VBP
to/TO
use/VB
the/DT
accumulated/VBN
A-CGH/NN
database/NN
to/TO
predict/VB
these/DT
diseases/NNS
in/IN
younger/JJR
age/NN
and/CC
prevent/VBP
them/PRP
./.
====================
